Posters
A comparison of the effectiveness of dorzolamide and acetazolamide in preventing early postoperative intraocular pressure rise following phacoemulsification surgery
Poster Details
First Author: M.Todorovic SERBIA
Co Author(s): S. Sreckovic
Abstract Details
Purpose:
To compare the effects of topical 2% dorzolamide and oral acetazolamide on preventing early intraocular hypertension after cataract surgery.
Setting:
Clinic of Ophthalmology, Clinical Centre Kragujevac, Serbia
Methods:
This prospective study was performed on 90 patients with cataracts who underwent phacoemulsification and implantation of an intraocular lens. They were randomly assigned to three groups of 30 patients - age, sex and IOP matched. The first group was a control group, the second received one drop of dorzolamide 2% one hour after surgery and the third group received oral acetazolamide (250 mg) one hour after surgery. Patients with previous eye disease and those developing complications were excluded. Goldmann applanation tonometry was performed on the day of the operation as well as 4, 24 hours and 7 days after surgery.
Results:
On the surgery day, there were no significant differences of mean preoperative IOP in groups. Four hours after surgery mean values were compared also without statistical difference between groups. Mean IOP values after 24 hours were 20.28 �Â�± 4.46 mmHg, second 17.71 �Â�± 4.91 mmHg and third 17.48 �Â�± 4.63 mmHg that shows statistically significant difference between control and two other groups (P < 0.05). Seven days after surgery mean IOP values were 16.97 �Â�± 3.36 mmHg, second 16.05 �Â�± 2.71mmHg and third 15.73 �Â�± 2.76 mmHg, suggesting there was a statistically significant difference between the first and third group.
Conclusions:
Administrating topical dorzolamide and oral acetazolamide had no effect on IOP measured 4 hours after surgery. After 24 hours, both groups showed the statistically significant difference of mean IOP comparing to control group. Both medicines have an approximately equal effect on preventing early IOP rise after phacoemulsification.
Financial Disclosure:
NONE
